A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
Phase 2
Completed
NCT04718896
| Condition | Moderate to Severe Plaque Psoriasis |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | UCB Biopharma SRL |
|---|
| Status | Completed |
|---|
| Enrollment | 41 participants |
|---|
| Interventions | bimekizumab |
|---|
| Start date | Apr 6, 2021 |
|---|
| Completion date | Mar 12, 2025 |
|---|
| Results posted | May 18, 2026 |
|---|
Summary
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
Plasma Concentration of Bimekizumab at Week 0
Baseline (Week 0) · microgram per milliliter (µg/mL)
| BKZ Dose A (320/160 mg) | NA ± NA microgram per milliliter (µg/mL) |
|---|
| BKZ Dose B (64/32 mg) | NA ± NA microgram per milliliter (µg/mL) |
|---|
Plasma Concentration of Bimekizumab at Week 1
Week 1 · µg/mL
| BKZ Dose A (320/160 mg) | 21.145 ± 33.510 µg/mL |
|---|
| BKZ Dose B (64/32 mg) | 3.811 ± 30.424 µg/mL |
|---|
Plasma Concentration of Bimekizumab at Week 4
Week 4 · µg/mL
| BKZ Dose A (320/160 mg) | 11.718 ± 35.259 µg/mL |
|---|
| BKZ Dose B (64/32 mg) | 1.986 ± 22.888 µg/mL |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.